Anti-influenza-virus broad-spectrum-neutrality neutralizing molecule 1E1
An influenza virus and molecule-binding technology, applied in antiviral agents, antiviral immunoglobulins, antibodies, etc., can solve the problems of restricting the large-scale use of chemical small molecule drugs and not recommending alkylamine drugs
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0179] Example 1, HA-specific memory B cells
[0180] Using FITC-CD19 / APC-IgG / Cy3-HA as specific markers, several HA-specific B cells were obtained.
Embodiment 2
[0181] Embodiment 2, antibody gene
[0182] RT-PCR and Nested-PCR method to obtain antibody heavy and light chain variable region genes, the molecular weight is about 400bp, β-actin is used as an internal reference (343bp), and the electrophoretic pattern is shown in figure 2 , image 3 and Figure 4 . The variable regions of heavy and light chain genes derived from the same B cell antibody were connected to T vectors, sequenced and constructed for expression vectors.
[0183] The 1E1 heavy chain variable region gene sequence is as follows (SEQ ID NO: 1):
[0184] GAGGTGCAGCTGGTGCAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCTCTGGATTCACCTTTAAC TGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCA CGGTTCACCATTCTCCAGAGACAATTCCAAGAAGACGTTGTATCTTCAAATGACCAGCCTGAGAGCCGAGGACACGGCCGTTTATTACTGTGCGAAA TTTGACTCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTAATC
[0185]Remarks: The sequences marked with double underlines are heavy chain genes CDR1 (SEQ ID NO:...
Embodiment 3
[0195] Embodiment 3, antibody expression
[0196] The results of ELISA showed that the fully human antibody was successfully expressed. Because the expression vector already contained the constant region of the heavy and light chain, the 293T cells transfected with the empty vector could also express the constant region of the heavy and light chain of the antibody. See Figure 5 .
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 